SeaStar Medical wins seventh Breakthrough Device tag for SCD in sepsis
SeaStar Medical Holding Corporation has received its seventh FDA Breakthrough Device Designation, this time covering the Selective Cytopheretic Device (SCD) therapy for the treatment of hyperinflammation in adult patients with sepsis or a septic condition. The Denver-based company said the designation, granted by the FDA's Centre for Biologics Evaluation and Research, is intended to accelerate development, assessment, and review for approval of the SCD in this indication.
The sepsis market represents a substantial unmet clinical need. Roughly 1.7 million US adults are affected annually, and the condition contributes to approximately one in three in-hospital deaths. No FDA-approved therapy currently exists to address the dysregulated inflammatory host response that drives organ failure in sepsis, making the indication a high-priority target for device and drug developers alike.
The SCD mechanism and the NEUTRALIZE-AKI trial
The SCD is designed to modulate overactivated immune cells, specifically targeting proinflammatory monocytes and activated neutrophils, without broadly suppressing immune function. The device is integrated with existing continuous renal replacement therapy systems, positioning it as an add-on to standard intensive care practice rather than a standalone treatment.
Chief Medical Officer Kevin Chung said the device "is designed to selectively modulate that response without broadly suppressing the immune system," adding that the breadth of Breakthrough Device Designations across seven indications "reinforces the disease-agnostic potential of the SCD platform to address dysregulated inflammation across multiple serious conditions."
SeaStar's ongoing NEUTRALIZE-AKI pivotal trial, which is evaluating the SCD in 339 adults with acute kidney injury requiring continuous renal replacement therapy, includes a pre-specified subgroup analysis of patients with sepsis or septic-like conditions. The company said it expects to have data from that cohort available to present to the FDA in the near term, though no timeline was specified. The trial's primary composite endpoint covers 90-day mortality and dialysis dependency at 90 days.
Market and competitive context
The sepsis immunomodulation space has a long history of clinical failures. Multiple drug candidates targeting cytokine pathways have not translated preclinical promise into approved therapies, leaving intensivists without targeted anti-inflammatory options beyond supportive care. The SCD's device classification, rather than a drug or biologic designation, means it follows a distinct regulatory pathway and is assessed on a different evidence framework, which may prove advantageous given the FDA's established Breakthrough Device programme for accelerating access in life-threatening conditions.
SeaStar's existing commercial product, QUELIMMUNE, was approved in 2024 under a Humanitarian Device Exemption for critically ill paediatric patients with acute kidney injury and sepsis requiring renal replacement therapy. Registry data from the first 21 paediatric patients showed a 76% survival rate at both Day 28 and Day 60, and no device-related adverse events, though the company notes that effectiveness has not been formally demonstrated under the HDE approval standard.
The adult sepsis designation extends the company's regulatory portfolio considerably. Investors will watch for the NEUTRALIZE-AKI sepsis subgroup readout and any subsequent FDA meeting request as the clearest near-term signal of whether the programme can advance toward a de novo or premarket approval submission.